8.02 USD
▼-0.59-6.85%
盘后 7.90 -1.50%
2026-11-20
市值
$41.17M
市盈率
—
EPS
-2.25
股息率
—
52 周区间
7.76 – 16.93
成交量
19.03K
Beta
0.45
目标价
44.00
52W 低 7.7652W 高 16.93
价格走势
公司简介
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients wit...